Thrombosis News and Research

Latest Thrombosis News and Research

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Angiotech Pharmaceuticals, Inc. today announced its financial results for the third quarter ended September 30, 2009.

9 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

Broadlane's partnership with CTC helps to deliver 24% average savings to its clients

Broadlane has delivered an average savings of 24 percent to healthcare clients by partnering with Compression Therapy Concepts (CTC), a certified, small-business, woman-owned diversity supplier of Deep Vein Thrombosis (DVT) prevention products. The relationship has also increased CTC’s market share within the Broadlane client base from less than 1 percent to approximately 60 percent.

21 Oct 2009

Age, gender and malignancies pose significant risk factors for TIVADs survival

It is common practice to insert totally implantable venous access devices (TIVADs) in cancer patients beginning a course of chemotherapy to eliminate potential peripheral venous access problems; however, risk factors impacting the survival of TIVADs remain unclear.

20 Oct 2009

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

New range of foods from marine animals and plants to help fight human diseases

Milk drinks that lower blood pressure, meat products that reduce the risk of heart disease, chocolate that calms you down and a new range of foods that can fight obesity can be created from marine animals and plants. Japan already has several product ranges on the shelves and research programmes are underway all over the world to create more.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Important issues facing nephrologists to be presented by Satellite Healthcare

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced that its chief researchers will present at The American Society of Nephrology (ASN) Renal Week 2009.

14 Oct 2009

Thrombosis News and Research

Latest Thrombosis News and Research

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

ThromboGenics issues business update for the third-quarter of 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Amgen publishes Phase 3 study results of Aranesp

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Data from multiple clinical and preclinical studies evaluating Hematide announced

Recruitment of Phase II trial of TB-402 completed ahead of schedule

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Broadlane's partnership with CTC helps to deliver 24% average savings to its clients

Age, gender and malignancies pose significant risk factors for TIVADs survival

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

New range of foods from marine animals and plants to help fight human diseases

More than half RCTs do not report vital information about study populations race, says study

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Important issues facing nephrologists to be presented by Satellite Healthcare

New device minimizes brain damage by speeding the delivery of post-stroke countermeasures

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

New cancer drugs boost drug spending

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in